AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01365676
Drug: GAMALINE®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
Trial: NCT01980082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01573442
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10.4 mg
Trial: NCT03649659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is being compared to the SDF and will also be applied twice
Trial: NCT03691090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03300648
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 3 percent hypertonic saline for a maximum of 7 days
Trial: NCT03635814
Drug: YD312 50mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YD312 50mg \* 1 + placebo 6 tablets
Trial: NCT03635814
Drug: YD312 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YD312 50mg \* 3 + placebo 6 tablets
Trial: NCT03635814
Drug: YD312 350mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YD312 50mg \* 7 tablets
Trial: NCT06182631
Drug: Vapocoolent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vapocoolent is a volatile refrigerated liquid, ie ethyl chloride, which is supposed to feel like the skin is numb before insertion of the IV.
Trial: NCT04274543
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline solution is a mixture of sodium chloride in water (9 g NaCl per liter water, 0.9% saline). Trephination allows for vascular growth and healing, especially in the inner avascular regions of the meniscus, by puncturing the meniscus. Small tunnels are created, which allow for healing factors to reach the avascular inner region of the meniscus from the vascular peripheral regions.
Trial: NCT03635814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YD312 0mg \* 7 tabets
Trial: NCT02564107
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
Trial: NCT00038584
Drug: SCH66336
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02104310
Drug: Fluorine-18-L-dihydroxyphenylalanine
RxNorm normalized name: L-3,4-dihydroxyphenylalanine
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 millicuries ± 10%; Intravenous injection; 1 time
Trial: NCT04077437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo with therapy during three experimental sessions
Trial: NCT01109173
Drug: Nepafenac Ophthalmic Suspension, 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
Trial: NCT01109173
Drug: Nepafenac Ophthalmic Suspension, 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
Trial: NCT00451594
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dose prednisone (Arm 2)~1. Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.~2. Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months
Trial: NCT02760043
Drug: LIA Combination Mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
Trial: NCT04016740
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative infusion
Trial: NCT03000127
Drug: AndroGel 1 % Topical Gel
RxNorm normalized name: AndroGel 1 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone gel
Trial: NCT03000127
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: NCT04166773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04072822
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01409161
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04423029
Drug: DF6002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT01214174
Drug: IBI-10090
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03342300
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.
Trial: NCT00000138
Drug: Prednisolone Phosphate
RxNorm normalized name: Prednisolone phosphate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02252536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
Trial: NCT00789750
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets appearing to be colesevelam
Trial: NCT00962390
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03199339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
Trial: NCT04391894
Drug: ECF843
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular eye drop
Trial: NCT00088998
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01271790
Drug: Copegus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Trial: NCT01271790
Drug: GS-9451 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching GS-9451 tablet QD
Trial: NCT01271790
Drug: Copegus®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Trial: NCT03538522
Drug: Placebo oral capsule QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of oral placebo capsule QD or 24 weeks
Trial: NCT03319901
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of chemotherapy is administered
Trial: NCT04431089
Drug: SHC014748M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Trial: NCT03202186
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule treatment
Trial: NCT01198379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03332797
Drug: LHRH Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The LHRH agonist (leuprolide acetate, goserelin acetate, or triptorelin pamoate) will be administered by injection once every 4 weeks on Day 1 of each 28-day cycle, according to the label. The investigator will choose the appropriate LHRH agonist approved for use in breast cancer.
Trial: NCT04227652
Drug: Ibuprofen administration
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of ibuprofen, according to treatment recommendations - per orally, into the nasogastric tube, or in the form of a suppository
Trial: NCT02353299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo single nighttime dose-1.5 hours
Trial: NCT02353299
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo single nighttime dose-4 hours
Trial: NCT01178996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02349009
Drug: C-82 Topical Gel, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active
Trial: NCT02349009
Drug: C-82 Topical Gel, Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03298542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to golimumab.
Trial: NCT02960997
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02797067
Drug: indomethacin suppository
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg rectal indomethacin 30min before ESWL
Trial: NCT00002951
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01182766
Drug: Placebo with brief behavioral enhancement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03675776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (prefilled syringe, weekly IV administration).
Trial: NCT03315091
Drug: Treatment A - AZD1775 administered under fasted conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Trial: NCT03315091
Drug: Treatment B - AZD1775 administered under fed conditions.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor.
Trial: NCT00584740
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg
Trial: NCT00584740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to AIN457
Trial: NCT01009281
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03860571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT01711671
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current approved standard of care
Trial: NCT02212561
Drug: methotrexate/hydrocortisone/cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
Trial: NCT02917928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
Trial: NCT01591356
Drug: EphA2-targeting DOPC-encapsulated siRNA
RxNorm normalized name: DOPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00334828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo; intravenous infusion.
Trial: NCT00004161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01056380
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, twice daily with food for 5 days
Trial: NCT03526874
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects, who continue to experience headache pain after the run-in step, receive 2 (2 mL) injections of the comparator.
Trial: NCT03267303
Drug: TS-091 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken once daily for 3 weeks
Trial: NCT02933827
Drug: ELIXCYTE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose-derived stem cells (ADSCs)
Trial: NCT03267303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally taken once daily for 3 weeks
Trial: NCT02419469
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.~Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.~Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.~Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.~Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.~Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.~Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses.
Trial: NCT02419469
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.~Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1.
Trial: NCT02419469
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.~Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly.
Trial: NCT02419469
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
Trial: NCT01682512
Drug: Rituxan®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01682512
Drug: MabThera®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03366688
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.
Trial: NCT01704040
Drug: CNTO 3157 (healthy participants)
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
Trial: NCT01704040
Drug: Placebo (healthy participants)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
Trial: NCT01704040
Drug: Placebo (asthmatic patients)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
Trial: NCT02953639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching Placebo to Basmisanil, as per the dosing schedules described above.
Trial: NCT03386240
Drug: Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of using Plus group (Triclosan-coated Sutures)
Trial: NCT00407680
Drug: Intensive therapy Valsartan,Fluvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01920386
Drug: Tramadol hydrochloride/Acetaminophen Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01920386
Drug: Tramadol hydrochloride/Acetaminophen SR Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01456377
Drug: predinose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg for kg for 3 wekees
Trial: NCT01456377
Drug: placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use a oral placebo
Trial: NCT04079673
Drug: Intravenous patient controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient controlled analgesia with morphine 1mg/ml for postoperative pain control
Trial: NCT00373061
Drug: Xolair®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This being an observational study, the study protocol does not specify any dose regimen.
Trial: NCT04059367
Drug: NNC9204-1177
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of NNC9204-1177 administered s.c. (subcutaneously, under the skin) in the stomach area once-weekly for 11 weeks
Trial: NCT00770354
Drug: AS1402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
Trial: NCT01676259
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfirinox or modified Folfirinox
Trial: NCT00517257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally once daily for 24 weeks
Trial: NCT01092065
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hard gelatin capsule to be taken bid for six weeks
Trial: NCT01908972
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg/kg/day for 16weeks
Trial: NCT02366975
Drug: Testosterone gel 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: testosterone gel 2% (50mg/die).
Trial: NCT02435342
Drug: dalazatide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
Trial: NCT02435342
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, Subcutaneous injection twice per week for a total of 9 doses
Trial: NCT00450385
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
Trial: NCT00450385
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
Trial: NCT01286831
Drug: [14C]GW642444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 200μg dose of \[14C\]GW642444 given on Day 1.
Trial: NCT01415128
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of Desipramine (50 mg) for 1 day
Trial: NCT00005578
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005578
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03483246
Drug: Sham-transplantation Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum.
Trial: NCT03679312
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide, which consists of breathing medical grade air (21% O2) with 40 parts per million of nitric oxide.
Trial: NCT03679312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo, which consists of breathing medical grade air (21% O2).
Trial: NCT03395132
Drug: Fucicort® Lipid cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.
Trial: NCT03395132
Drug: Fucidin® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.
Trial: NCT03395132
Drug: Fucicort® Lipid cream vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.
Trial: NCT03586037
Drug: AD-2012 80mg
RxNorm normalized name: PrameGel Reformulated Apr 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD-2012 80mg tablet